Clinical evaluation In the health outcome of patients with bronchial asthma at the first visit and unscheduled visit with budesonide/formoterol therapy

Clinical evaluation In the health outcome of patients with bronchial asthma at the first visit and unscheduled visit with budesonide/formoterol therapy - Clinical evaluation In the health outcome of patients with bronchial asthma at the first visit and unscheduled visit with budesonide/formoterol therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028486

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchial asthma

Interventions

Budesonide160mcg/Formoterol4.5mcg once 2 inhalation,b.i.d.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who meet following criteria 1)Man or woman who is 20 years old or older at the time of getting informed consent 2)Patients diagnosed with asthma 3)Patient whose value of FeNO more than 40 ppb

Exclusion criteria

Exclusion criteria: Following are exclusion criteria 1)Patient with the drug allergy 2)Infection in the absence of effective antimicrobial agents,patients with deep mycosis 3)Patients with tuberculous disease,or respiratory infection 4)Patients with abnormal chest X-ray image 5)Patients with respiratory disease and other respiratory infections in 8 weeks before inclusion 6)Patients are using the b-blockers, including eye drops or patients with systemic corticosteroids to less than 30 days 7)Patients with serious complications 8)Smoking history of 10 pack years or more and with less than 6 months or by non smoking 9)Patients with pregnancy,or who hope for a pregnancy 10)Patients were deemed inappropriate research attending physician is incorporated into this study

Design outcomes

Primary

Measure	Time frame
Improvement ratio (%) for the health outcome (degree of suffering and trouble; VAS value) by BUD/FM	—

Secondary

Measure	Time frame
Comparison of the followings between at the baseline and at 4 weeks; -ACQ score -FeNO -Airway resistance with IOS -%FEV1.0 -Frequency of SABA use	—

Countries

Japan

Contacts

Public ContactHozawa Soichiro

Hiroshima Allergy and Pulmonary Clinic Department of allergy

hozawa@vesta.ocn.ne.jp082-568-1167

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026